B6Rcc.129-Cd44tm1.1Ugu/Cnrm

Status

Available to order

EMMA IDEM:01994
International strain nameB6Rcc.129-Cd44tm1.1Ugu/Cnrm
Alternative nameC57 BL/6RCC CD44v6v7-/-
Strain typeTargeted Mutant Strains : Knock-out
Allele/Transgene symbolCd44tm1.1Ugu
Gene/Transgene symbolCd44

Information from provider

ProviderUrsula Günthert
Provider affiliationInstitut für Pathologie, University of Basel
Genetic informationA loxP site was inserted 3' of exon v6 and a neomycin resistance cassette, with a 5' loxP site, was inserted 5' of exon v6 of the Cd44 gene. During insertion, 1.6 kb of sequence was lost in the exon v7 region; cre recombinase was transiently expressed in ES cells allowing the removal of neomycin cassette and exon v6. Mice lack both exon v6 and v7.
Phenotypic informationCd44v6v7-/-: Strongly reduced symptoms in autoimmune diseases and haemopoiesis.
Breeding history10 generations backcrossed onto C57BL/6Rcc; currently bred as C57BL/6Rcc Cd44v6v7-/-.
References
  • Abrogation of experimental colitis correlates with increased apoptosis in mice deficient for CD44 variant exon 7 (CD44v7).;Wittig B M, Johansson B, Zöller M, Schwärzler C, Günthert U, ;2000;The Journal of experimental medicine;191;2053-64; 10859330

Information from EMMA

Archiving centreCNR, Consiglio Nazionale delle Ricerche, Monterotondo, Italy

Disease and phenotype information

MGI phenotypes (allele matching)
  • decreased susceptibility to experimental autoimmune encephalomyelitis / MGI
  • decreased T cell proliferation / MGI
  • abnormal digestive system physiology / MGI
  • immune system phenotype / MGI
  • abnormal T-helper 1 physiology / MGI
  • abnormal T-helper 2 physiology / MGI
MGI phenotypes (gene matching)
  • decreased mast cell number / MGI
  • altered response to myocardial infarction / MGI
  • abnormal cell morphology / MGI
  • decreased mast cell histamine storage / MGI
  • abnormal uterus morphology / MGI
  • thin epidermis / MGI
  • abnormal lipid level / MGI
  • abnormal vasculogenesis / MGI
  • abnormal digestive system physiology / MGI
  • impaired wound healing / MGI
  • impaired macrophage phagocytosis / MGI
  • liver inflammation / MGI
  • lung inflammation / MGI
  • abnormal definitive hematopoiesis / MGI
  • no abnormal phenotype detected / MGI
  • abnormal CD4-positive, alpha beta T cell morphology / MGI
  • abnormal neutrophil physiology / MGI
  • short tibia / MGI
  • impaired skin barrier function / MGI
  • delayed wound healing / MGI
  • decreased myocardial infarction size / MGI
  • abnormal leukocyte migration / MGI
  • peritoneal inflammation / MGI
  • decreased susceptibility to induced arthritis / MGI
  • decreased tumor growth/size / MGI
  • abnormal leukocyte adhesion / MGI
  • abnormal physiological neovascularization / MGI
  • increased susceptibility to induced arthritis / MGI
  • enhanced coordination / MGI
  • decreased cholesterol level / MGI
  • abnormal vascular endothelial cell physiology / MGI
  • decreased susceptibility to kidney reperfusion injury / MGI
  • abnormal miniature excitatory postsynaptic currents / MGI
  • decreased susceptibility to experimental autoimmune encephalomyelitis / MGI
  • increased mean systemic arterial blood pressure / MGI
  • abnormal CD8-positive, alpha beta T cell morphology / MGI
  • abnormal response to infection / MGI
  • increased susceptibility to parasitic infection / MGI
  • impaired natural killer cell mediated cytotoxicity / MGI
  • decreased acute inflammation / MGI
  • increased acute inflammation / MGI
  • decreased T cell proliferation / MGI
  • digestive/alimentary phenotype / MGI
  • immune system phenotype / MGI
  • hematopoietic system phenotype / MGI
  • abnormal CD4-positive, alpha-beta T cell physiology / MGI
  • abnormal T-helper 1 physiology / MGI
  • abnormal T-helper 2 physiology / MGI
  • choroidal neovascularization / MGI
  • decreased circulating creatinine level / MGI
  • decreased blood urea nitrogen level / MGI
  • abnormal vascular smooth muscle physiology / MGI
  • decreased angiogenesis / MGI
  • decreased susceptibility to type IV hypersensitivity reaction / MGI
  • abnormal cell physiology / MGI
  • abnormal vascular endothelial cell morphology / MGI
  • abnormal involution of the mammary gland / MGI
  • increased diameter of tibia / MGI
  • abnormal osteoclast differentiation / MGI
  • increased circulating tumor necrosis factor level / MGI
  • decreased circulating tumor necrosis factor level / MGI
  • increased tumor necrosis factor secretion / MGI
  • abnormal interleukin secretion / MGI
  • increased circulating interferon-gamma level / MGI
  • increased circulating interleukin-2 level / MGI
  • increased interleukin-1 beta secretion / MGI
  • increased interleukin-10 secretion / MGI
  • increased interleukin-6 secretion / MGI
  • impaired neutrophil recruitment / MGI
  • abnormal chemokine secretion / MGI
  • decreased transforming growth factor level / MGI
  • decreased sensitivity to induced cell death / MGI
  • abnormal epidermal lamellar body morphology / MGI
  • increased sensitivity to induced morbidity/mortality / MGI
  • abnormal circulating chemokine level / MGI
  • abnormal circulating cytokine level / MGI
  • decreased activation-induced cell death of T cells / MGI
  • increased mitochondria size / MGI
  • abnormal mitochondrial crista morphology / MGI
  • decreased fibroblast proliferation / MGI
  • impaired leukocyte tethering or rolling / MGI

Literature references

  • Abrogation of experimental colitis correlates with increased apoptosis in mice deficient for CD44 variant exon 7 (CD44v7).;Wittig B M, Johansson B, Zöller M, Schwärzler C, Günthert U, ;2000;The Journal of experimental medicine;191;2053-64; 10859330

Information on how we integrate external resources can be found here

Order

Availabilities

Requesting frozen sperm or embryos is generally advisable wherever possible, in order to minimise the shipment of live mice.

  • Frozen embryos. Delivered in 4 weeks (after paperwork in place). €1740*
  • Rederivation of mice from frozen stock, delivery time available upon request . €3880*

Due to the dynamic nature of our processes strain availability may change at short notice. The local repository manager will advise you in these circumstances.

* In addition users have to cover all the shipping costs (including the cost for returning dry-shippers, where applicable).

More details on pricing and delivery times

Practical information

Example health report
(Current health report will be provided later)

Material Transfer Agreement (MTA)
For this strain no provider MTA is needed. Distribution is based on the EMMA conditions only.

EMMA conditions
Legally binding conditions for the transfer

Other EMMA strains

Not found what you were looking for? Search here for other strains available from EMMA.


Search
INFRAFRONTIER® and European Mouse Mutant Archive - EMMA® are registered trademarks at the European Union Intellectual Property Office (EUIPO).